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These guidelines do not establish a standard of care to be followed in every case. It is
recognized that each case is different and those individuals involved in providing health care are
expected to use their judgment in determining what is in the best interests of the patient based
on the circumstances existing at the time. It is impossible to anticipate all possible situations
that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Asthma Exacerbation Clinical Practice Guideline
Asthma Exacerbation Continuum Algorithm

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved in providing health
care are expected to use their judgment in determining what is in the best interest of the patient based on the circumstances existing at the time. It is impossible to anticipate all
possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide care with the understanding that departures from them may be
required at times.
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Asthma Exacerbation: Ambulatory Algorithm

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and
those individuals involved in providing health care are expected to use their judgment in determining what is in the best interest of
the patient based on the circumstances existing at the time. It is impossible to anticipate all possible situations that may exist and to
prepare guidelines for each. Accordingly, these guidelines should guide care with the understanding that departures from them may
be required at times.
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Asthma Exacerbation: Urgent Care Algorithm

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and
those individuals involved in providing health care are expected to use their judgment in determining what is in the best interest of
the patient based on the circumstances existing at the time. It is impossible to anticipate all possible situations that may exist and to
prepare guidelines for each. Accordingly, these guidelines should guide care with the understanding that departures from them may
be required at times.
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Asthma Exacerbation: Emergency Department Algorithm

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and
those individuals involved in providing health care are expected to use their judgment in determining what is in the best interest of
the patient based on the circumstances existing at the time. It is impossible to anticipate all possible situations that may exist and to
prepare guidelines for each. Accordingly, these guidelines should guide care with the understanding that departures from them may
be required at times.
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Asthma Exacerbation: Inpatient Algorithm

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and
those individuals involved in providing health care are expected to use their judgment in determining what is in the best interest of
the patient based on the circumstances existing at the time. It is impossible to anticipate all possible situations that may exist and to
prepare guidelines for each. Accordingly, these guidelines should guide care with the understanding that departures from them may
be required at times.
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Objective of Guideline

To provide care standards for the patient diagnosed with asthma exacerbation throughout the care continuum.

Background

Efficient and effective treatment of asthma exacerbation is key to decreasing need for hospitalization, decreasing
length of stay when hospitalization is required, reducing readmissions, and mitigating adverse safety events. At
Children’s Mercy Hospital, patients with asthma exacerbations may receive care in the ambulatory clinics, Urgent
Care Clinics (UCC), Emergency Departments (ED), Medical/Surgical inpatient units, or Pediatric Intensive Care. It is
imperative that we provide consistency of care and safe transitions between care settings. This Clinical Practice
Guideline (CPG) provides evidence-based strategies and decision support for providers caring for patients with
asthma exacerbation.

Target Users
•

•
•
•

Physicians (Ambulatory, Urgent Care, Emergency Department, Hospital Medicine, Community Physicians,
Fellows, Resident Physicians)
Nurse Practitioners
Nurses
Respiratory Therapists

Target Population

Guideline Inclusion Criteria
•
Patients experiencing asthma exacerbations.
•
Sign and symptoms: acute onset of wheezing, coughing, and/or breathlessness with known or suspected
asthma.

Guideline Exclusion Criteria
•
Patients less than two years of age.
•
Patients with other chronic pulmonary conditions aside from asthma.
•
Long-term care of asthma without current exacerbation

AGREE

The EPR-4 national guideline and the GINA international guideline provided guidance to the Asthma Exacerbation
Committee (Asthma, 2021; Expert Panel Working Group of the National Heart et al., 2020). See Tables 1 and 2
for AGREE II.

Table 1.
AGREE IIa Summary for the EPR-4 Guideline
Domain

Percent Agreement

Scope and purpose

94%

Stakeholder involvement

92%

Rigor of development

82%

Clarity and presentation

94%

Applicability

45%

Percent Justification
The clinical questions posed, and target populations were
identified. The aim of the guideline was not found in the
guideline.
The guideline was developed by the appropriate
stakeholders and convened focus groups of patients and
caregivers to garner input on their preferences and values.
The guideline did not explicitly identify the target users,
but it seems aimed at pulmonologists, allergists and PCPs.
The process used to gather and synthesize the evidence
and the methods to formulate the recommendations were
explicitly stated. The guideline developers did not provide
how the guidelines will be updated.
The guideline recommendations are clear, unambiguous,
and easily identified; in addition, different management
options are presented.
Implementation guidance, including equipment costs and
medication efficacy, were provided in the guideline. The
guideline did not address barriers and facilitators that

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and
those individuals involved in providing health care are expected to use their judgment in determining what is in the best interest of
the patient based on the circumstances existing at the time. It is impossible to anticipate all possible situations that may exist and to
prepare guidelines for each. Accordingly, these guidelines should guide care with the understanding that departures from them may
be required at times.
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could be faced during implementation, monitoring or audit
criteria, nor other resource costs associated with guideline
implementation.
The recommendations were not biased with competing
Editorial independence
94%
interests.
Note: Four EBP Scholars completed the AGREE II on this guideline.
Table 2.
AGREE IIa Summary for the GINA Guideline (Asthma, 2021)
Percent Justification
Domain
Percent Agreement
The aim of the guideline, the clinical questions posed, and
target populations were identified.
It is unclear if the guideline included appropriate
Stakeholder involvement
61%
stakeholders. It is unclear if the patient’s viewpoint was
sought.
The guideline developers did not provide how the evidence
Rigor of development
73%
was gathered and synthesized, how the recommendations
were formulated.
The guideline recommendations are clear, unambiguous,
Clarity and presentation
97%
and easily identified; in addition, different management
options are presented.
Recommendations for monitoring adherence and treatment
Applicability
90%
response are included.
It is unclear if the recommendations were biased by
Editorial independence
63%
competing interests.
Note: Four EBP Scholars completed the AGREE II on this guideline.
Scope and purpose

94%

Practice Recommendations

The National Asthma Education and Prevention Program’s Expert Panel Report-3 (EPR-3) defines asthma exacerbation
as an episode of “progressively worsening shortness of breathing, cough, wheezing, and chest tightness-or some
combination of these symptoms” (National Asthma & Prevention, 2007). Managing asthma exacerbation in the
primary or acute care settings first requires assessment of exacerbation severity based on respiratory rate, oxygen
saturation, auscultation, and dyspnea (Global Initiative for Asthma, 2019; Kelly et al., 2000). Therapy with short
acting beta agonist (e.g., albuterol) and supplemental oxygen, if needed, should be initiated early while assessing
severity, see Appendix A (Kelly et al.) and considering alternative diagnoses (e.g., anaphylaxis; foreign body
aspiration). Chest radiography and laboratory studies are not routinely needed (Global Initiative for Asthma, 2019;
National Asthma & Prevention, 2007).
For severe exacerbations, immediate transfer to an acute care facility should be arranged. Intensive care may be
needed for patients with lethargy, confusion, or minimal breath sounds on auscultation. Patients with severe
exacerbations should be given albuterol, ipratropium bromide, magnesium sulfate, systemic corticosteroid (IV), and
supplemental oxygen without delay (Global Initiative for Asthma, 2019; National Asthma & Prevention, 2007).
For moderate exacerbations, albuterol should be provided via continuous nebulization or repeated doses via metered
dose inhaler (MDI) and spacer set up. Systemic corticosteroid (oral) should be given early in the course of treatment.
Response to treatment should be assessed frequently to guide subsequent therapeutic interventions and assess the
need for transfer to a higher level of care which may include hospitalization (Global Initiative for Asthma, 2019;
National Asthma & Prevention, 2007).
For mild exacerbations, albuterol should be provided via MDI and repeated as necessary. If more than 2 doses of
albuterol are required, systemic corticosteroids (oral) should be administered. Response to treatment should be
assessed frequently to guide subsequent therapeutic interventions and timing of potential discharge home.
For all patients experiencing asthma exacerbations, long-term home asthma care must be addressed. Patients should
be instructed to start or step-up controller therapy. Patient/family education is essential. Education should include a
written asthma action plan, instructions on correct inhaler technique with emphasis on the importance of medication
compliance, strategies to mitigate environmental triggers, and review of early signs of worsening asthma. Follow-up
* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and
those individuals involved in providing health care are expected to use their judgment in determining what is in the best interest of
the patient based on the circumstances existing at the time. It is impossible to anticipate all possible situations that may exist and to
prepare guidelines for each. Accordingly, these guidelines should guide care with the understanding that departures from them may
be required at times.
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within 2-7 days should be arranged (Expert Panel Working Group of the National Heart et al., 2020; Global Initiative
for Asthma, 2019; National Asthma & Prevention, 2007)

Additional Questions Posed by the CPG Committee

The Expert Panel Report – 3 (EPR-3), Expert Panel Report – 4 (EPR-4), and the Global Initiative for Asthma (GINA)
guidelines provided guidance to the Asthma Exacerbation Clinical Practice Guideline Committee (see Table 1 and 2 for
AGREE II). While Children’s Mercy adopted most of these practice recommendations, two additional questions posed
by the CPG Committee led to further clarifications in care:
1.

In a child > 2 years old with an acute asthma exacerbation, are 1 to 2 doses of dexamethasone as effective as
5-day course of prednisolone in the prevention of symptom recurrence?
While the Asthma CPG Committee recommends use of systemic steroid in non-intensive care settings at
Children’s Mercy, the committee is unable to recommend for or against the use of a one-to-two-day course of
dexamethasone (intervention) in comparison to prednisolone (comparator), based on the GRADE Evidence to
Decision instrumenta found in the Summary of Findings Table (see Table 1)a. The overall certainty in the
evidence is low to very lowa. Two systematic reviews and five single studies support use of dexamethasone
and prednisolone in treatment of acute asthma exacerbations and both systemic steroids are effective in
prevention of symptom recurrence.
The Asthma CPG Subcommittee discussed additional considerations using the GRADE Evidence to Decision
instrumenta found in the Appendix. The CPG Committee through consensus agreed on a conditional
recommendation for dexamethasone as the systemic steroid of choice in non-intensive care settings at
Children’s Mercy based on feasibility, value, and compliance for all stakeholders (see Appendix B).

2.

In children aged 0 – 18 years with asthma and admitted to the hospital for an exacerbation, should the
dosage of quick relief albuterol medicine via MDI be based on weight versus based on age better for
improved outcomes (decreased length of stay and respiratory scores) and fewer side effects (increased HR,
hyperactive, nausea/vomiting, arrhythmia, irritably)?
No recommendation can be made for weight or age-based MDI albuterol administration, based on expert
review of current literature by the Department of EBP. No studies were found that answered the specific care
question of weight versus age dosing for albuterol. When there is a lack of scientific evidence, standard work
should be developed, implemented, and monitored (see Appendix C). To maintain consistency throughout the
continuum of care at Children’s Mercy, the committee opted for weight-based dosing.

Measures
•
•
•
•
•

Use of Asthma Exacerbation Power Plan (UCC, ED, inpatient)
Provision of dexamethasone as systemic steroid of choice for mild to moderate asthma exacerbations (UCC,
ED, inpatient)
Length of stay (inpatient)
Readmissions within 72 hours of inpatient discharge
Revisits to the UCC or ED within 72 hours within UCC or ED visit

Potential Cost Implications

The following potential improvements may reduce costs and resource utilization for healthcare facilities and reduce
healthcare costs and non-monetary costs (e.g., missed school/work, loss of wages, stress) for patients and families.
•
Decreased frequency of admission
•
Decreased inpatient length of stay
•
Decrease in readmission or acute care facility re-evaluation in less than seven days of initial exacerbation
•
Decreased time to treatment in the ED setting
•
Increased safety of patient transfer between settings
•
Decreased unwarranted variation in care
•
Narrowing gaps in health care disparities related to inequities in transportation, health literacy, and
medication compliance

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and
those individuals involved in providing health care are expected to use their judgment in determining what is in the best interest of
the patient based on the circumstances existing at the time. It is impossible to anticipate all possible situations that may exist and to
prepare guidelines for each. Accordingly, these guidelines should guide care with the understanding that departures from them may
be required at times.
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Potential Organizational Barriers and Facilitators

Barriers
•
Variability of acceptable level of risk among providers
•
Different clinical perspectives among providers are various care settings (acute care, subspecialty care)
•
Challenges with follow-up faced by some families
Facilitators
•
Collaborative engagement across care continuum settings during CPG development
•
High rate of use of CPG and order sets
•
Standardized order set for Urgent Care, Emergency Department, Hospital Medicine, and Pediatric
Intensive Care

Power Plans
•
Ambulatory Clinics (see Appendix D)
•
Urgent Care (see Appendix E)
•
Emergency Department (see Appendix F)
•
Pediatric Intensive Care (see Appendix G)
•
Hospital Medicine (see Appendix H)
Associated Policies
• Division of Emergency Medicine: Asthma Initiation Standing Order
•
Continuous Albuterol Administration
Guideline Preparation

This guideline was prepared by the Evidence Based Practice (EBP) Department in collaboration with the Asthma
Exacerbation CPG Committee composed of content experts at Children’s Mercy Kansas City. Development of this
guideline supports the Division of Service and Performance Excellence’s initiative to promote care standardization that
builds a culture of quality and safety that is evidenced by measured outcomes. If a conflict of interest is identified, the
conflict will be disclosed next to the team member’s name.

Asthma Exacerbation CPG Committee Members and Representation
•
•
•
•
•
•
•
•
•
•
•

Jade Tam-Williams, MD | Pulmonology | Committee Chair
Madison Buchanan, BHS, RRT-NPS | Respiratory Care | Committee Member
Marc Sycip, MD | Emergency Medicine | Committee Member
Matthew Johnson, MD | Hospital Medicine | Committee Member
Nathan Carman, BA RRT-NPS | Respiratory Care | Committee Member
Claire Seguin, MD | Hospital Medicine Fellow | Committee Member
Erin Scott, DO | Emergency Medicine | Committee Member
Aarti Pandya, MD | Allergy & Immunology | Committee Member
Amanda Nedved, MD | Urgent Care | Committee Member
Helen Murphy, MHS, HCEd, RRT, AE-C | Respiratory Care | Committee Member
Caroline Holton, MD | Critical Care Fellow | Committee Member
MIT Committee Members
• George Abraham, MD | Emergency Medicine, Medical Informatics
• Ashly Catalino | Medical Informatics - Ambulatory
• Tammy Frank, RPh, CPHIMS | Medical Informatics - Pharmacy
• Brandan Kennedy, MD | Hospital Medicine, Human Factors Collaborative, Medical Informatics
• Amber Lanning | Medical Informatics – general inpatient
• Ryan McDonough, DO | Endocrinology, Medical Informatics
• Tracy Taylor | Medical Informatics – ED, UCC

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and
those individuals involved in providing health care are expected to use their judgment in determining what is in the best interest of
the patient based on the circumstances existing at the time. It is impossible to anticipate all possible situations that may exist and to
prepare guidelines for each. Accordingly, these guidelines should guide care with the understanding that departures from them may
be required at times.
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EBP Department Members:
• Kathleen Berg, MD, FAAP | Evidence Based Practice & Hospital Medicine
• Jacqueline Bartlett, PhD, RN | Evidence Based Practice
• Andrea Melanson, OTD, OTR/L | Evidence Based Practice

Additional Review & Feedback
•

•

The CPG was presented to each division or department represented on the CPG committee as well as other
appropriate stakeholders. Feedback was incorporated into the final product.
The CPG was reviewed by an internal and external reviewer using the AGREE II instrument (see Appendix I).

Implementation & Follow-Up
•

•
•

•
•
•

•

Order sets consistent with CPG recommendations were created for each care setting (Emergency Department,
Inpatient, Intensive Care).
“Quick Orders” were updated for Urgent Care and Emergency Department.
The Asthma Initiation Standing Order policy was updated. This details a process for nursing staff in the
Emergency Department to determine severity of asthma exacerbation based on the Pediatric Asthma Score
and provide albuterol and/or systemic steroids based on a standing order. This was approved by the Medical
Executive Committee, Nursing Practice Council, and Pharmacy & Therapeutics Committee.
The Continuous Albuterol Administration policy was updated to use weight-based rather than age-based
albuterol dosing in all care settings in which continuous albuterol is administered. This was approved by the
Pharmacy & Therapeutics Committee.
The Respiratory Care Albuterol Weaning Protocol was updated to further standardize the dose and interval of
albuterol throughout the weaning process and to maintain consistency with the CPG. This was approved by the
Department of Respiratory Care.
Education was provided to all stakeholders:
Nursing units where the Asthma Initiation Standing Order is used
Department of Respiratory Care
Providers from Urgent Care, Emergency Medicine, Hospital Medicine
Resident physicians
Additional institution-wide announcements were made via email, hospital website, and relevant huddles.
Metrics will be assessed and shared with appropriate care teams to determine if changes need to occur.

Guideline Development Funding

The development of this guideline was underwritten by the following departments/divisions: EBP, Pulmonology,
Respiratory Care, Emergency Medicine, Hospital Medicine, Urgent Care, and Allergy & Immunology.

Approval Process

This guideline was reviewed and approved by the Asthma CPG Committee, Content Expert Departments/Divisions, and
the EBP Department; after which they were approved by the Medical Executive Committee. Guidelines are reviewed
and updated as necessary every 3 years within the EBP Department at CMKC. Content expert teams are involved with
every review and update.

Approval Obtained

Department/Unit
Pulmonology
Allergy & Immunology
Respiratory Care
Pediatric Intensive Care Unit
Emergency Medicine
Hospital Medicine
Urgent Care
Medical Executive Committee

Date Approved
April 2022
April 2022
April 2022
April 2022
April 2022
April 2022
April 2022
July 2022

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and
those individuals involved in providing health care are expected to use their judgment in determining what is in the best interest of
the patient based on the circumstances existing at the time. It is impossible to anticipate all possible situations that may exist and to
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Version History
Date
10/2016
5/2019

7/6/2022

Comments
Version 1a: Inpatient care standards based on EPR-3 and GINA guidelines.
Version 1b: Emergency Department and Urgent Care Clinics care standards based on EPR-3
and GINA guidelines
Version two: Updated all previous guidelines (Urgent Care Clinics, Emergency Department,
and Inpatient) and developed new guidelines (Care Continuum, and Ambulatory) using the
EBP-4 (2020) and GINA (2021) guidelines as foundational guidelines.

Date for Next Review: July 2025
Disclaimer

When evidence is lacking or inconclusive, options in care are provided in the guideline and the power plans that
accompany the guideline.
These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is
different, and those individuals involved in providing health care are expected to use their judgment in determining
what is in the best interests of the patient based on the circumstances existing at the time.
It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly,
these guidelines should guide care with the understanding that departures from them may be required at times.
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* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different, and
those individuals involved in providing health care are expected to use their judgment in determining what is in the best interest of
the patient based on the circumstances existing at the time. It is impossible to anticipate all possible situations that may exist and to
prepare guidelines for each. Accordingly, these guidelines should guide care with the understanding that departures from them may
be required at times.
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Appendix A: Severity of Asthma Exacerbation
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Appendix B: Dexamethasone versus prednisolone critically appraised topic
Specific Care Question #1:
In a child greater than 2 years old with an acute asthma exacerbation, are 1-2 doses of dexamethasone (intervention) as effective as a 5-day course of
prednisolone (comparator) in prevention of symptom recurrence?
Recommendations from the Asthma CPG Committee and Based on Current Literature
While the Asthma Clinical Practice Guideline (CPG) Committee recommends use of systemic steroid in non-intensive care settings at Children’s Mercy,
the committee is unable to recommend for or against the use of a one-to-two-day course of dexamethasone (intervention) in comparison to
prednisolone (comparator), based on the GRADE Evidence to Decision instrumenta found in the Summary of Findings Table (see Table 1)a. The overall
certainty in the evidence is low to very lowa. Two systematic reviews and five single studies support use of dexamethasone and prednisolone in
treatment of acute asthma exacerbations and both systemic steroids are effective in prevention of symptom recurrence.
The Asthma CPG Subcommittee discussed additional considerations using the GRADE Evidence to Decision instrumenta found in the Appendix. The CPG
Committee through consensus agreed on a conditional recommendation for dexamethasone as the systemic steroid of choice in non-intensive care
settings at Children’s Mercy based on feasibility, value, and compliance for all stakeholders (see Appendix).
Literature Summary
Background
Acute asthma exacerbations are a leading cause for patients seeking emergent medical care at acute care centers and, although most patients are
discharged within the same day, relapse of symptoms is still common requiring additional medical care and return to an acute care center (Kirkland et al.,
2018). Systemic corticosteroids are a primary part of the treatment regimen for moderate to severe asthma exacerbations with dexamethasone and
prednisolone most often prescribed (Fuhlbrigge et al., 2012). In spite of the proven efficacy of dexamethasone and prednisolone, these steroids, along with
others, require the balance of benefits against the potential adverse events such as nausea, vomiting, or gastrointestinal distress (Normansell et al., 2016).
Evidence is limited to which medications and dosing provide maximum recovery from acute exacerbations in children, specifically to decrease relapse in
symptoms. This review will summarize identified literature to answer the specific care question.
Study Characteristics
The search for suitable studies was completed on September 8, 2021. Amanda Nedved, MD, Erin Scott, DO, and Claire Seguin, MD reviewed the 42 titles
and/or abstracts found in the search and identifiedb five systematic reviews and six single studies believed to answer the question. After an in-depth review
of the identified systematic reviewsa and single studiesa, two systematic reviews and five single studies answered the question.
Race/Ethnicity Race and ethnicity as defined by the individual authors were reviewed in the literature. Of the three studies that reported on race
and ethnicity, 50-70% of participants were either black or Hispanic.
Are one to two doses of dexamethasone as effective as a five-day course of prednisolone in prevention of symptom recurrence?
Elkhharwili et al. (2020) recruited 60 patients aged 2-11 years and randomized into three groups. For purposes of this review, only group 1: single
dose of 0.3 mg/kg dexamethasone and group 3: five days of 1.5 mg/kg/day prednisolone were compared for relapse rate of symptoms over five
days.
Hermani et al. (2021) completed a retrospective review of 1,410 patients aged 3-21 years of age. The authors measured relapse of symptoms
based on two interventions: receipt of dexamethasone or prednisolone prior to presentation to the emergency department (ED) and receipt of
If you have questions regarding this Specific Care Question – please contact evidencebasedpractice@cmh.edu
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dexamethasone or prednisolone after ED presentation. All four groups received oral dexamethasone (0.5 mg/kg/day for a median of 1 day) or
prednisolone (average dose of 1.8 mg/kg/day for median of 2 days) after arrival to the hospital.
Kirkland et al. (2018), a systematic review, reported on both adult and pediatric studies to analyze the optimal delivery method (oral or
intramuscular) of dexamethasone compared to oral prednisolone. Only the pediatric studies are included in this review (Al-Wahadneh et al., 2006;
Gordon et al., 2007; Gries et al., 2000; Klig et al., 1997). The primary outcome of relapse of symptoms was defined by the authors as any
unscheduled visit to a health practitioner for worsening asthma symptoms or requiring subsequent treatment with corticosteroids. Reported relapse
data within 10 days of discharge from the ED were reported.
Normansell et al. (2016), a systematic review, reviewed both adult and pediatric studies to analyze higher dose/longer course versus lower
dose/shorter course for the outcome of re-admission during the follow-up period. Only the pediatric studies are included in this review (Altamimi et
al., 2006; Cronin et al., 2015; Greenberg et al., 2008; Qureshi et al., 2001). The pediatric studies compared a single dose (0.6 mg/kg) of
dexamethasone to a five-day dosing of prednisolone (2mg/kg). Relapse of symptoms, up to 15 days post discharge from the ED, was used as the
parameters for follow up.
Paniagua et al. (2017) analyzed data on 557 randomized patients aged 1-14 years comparing the impact of two doses of dexamethasone to five
days of prednisolone for relapse of symptoms defined as a return visit to the ED.
Volk et al. (2019) completed a retrospective review of a two-day course of dexamethasone to a five-day course of prednisolone on symptom
recurrence within one week of initial visit to a hospital emergency department.
Watnick et al. (2016) analyzed the impact of a single dose of dexamethasone to a three-to-five-day course of prednisolone on relapse of symptoms
in patients presenting to an area emergency room aged 3-17 years. Those that returned within 72 hours of discharge from the emergency room
were counted as having a relapse but were only counted for their initial return.
Summary by Outcome
Relapse of Symptoms with 1 Day of Dexamethasone vs. 3-5 Days of Prednisolone.
Four studies (Elkharwili et al., 2020; Kirkland et al., 2018; Normansell et al., 2016; Watnick et al., 2016 measured the relapse in symptoms of an asthma
exacerbation within 14 days following initial presentation, (n = 9,424). Based on the pediatric studies (n = 615) identified in the two systematic reviews
(Kirkland et al, 2018; Normansell et al., 2016), the OR = 0.74, 95% CI [0.32, 1.69], p = .47 indicated the intervention of one day dosing of
dexamethasone was not different to the comparator of three to five days dosing of prednisolone (see Figure 2 & Table 1). For the RCT study (Elkharwili et
al., 2020), (n = 8,769), the OR = 0.63, 95% CI [.40, 1.01], p = .05 indicated the intervention of one day dosing of dexamethasone was not different to the
three to five days dosing of prednisolone (see Figure 3 & Table 1). The cohort study (Watnick et al., 2016), (n = 40), MD = 3.00, 95% CI [-14.67, 20.67], p
= .74 indicated the intervention of one day dosing of dexamethasone was not different to the comparator of three to five days dosing of prednisolone (see
Figure 4 & Table 1).
Certainty of the Evidence For Relapse of Symptoms with 1 Day of Dexamethasone vs. 3-5 Days of Prednisolone. The certainty of the body
of evidence was low to very low. The body of evidence for the two systematic reviews (Kirkland et al., 2018; Normansell et al., 2016) was assessed to
have serious risk of bias as demonstrated by lack of blinding of study participants and study personnel and serious imprecision due to low number of
events (n = 35). The body of evidence for the RCT (Elkharwili et al., 2020) was found to have serious risk of bias as demonstrated by data analysis
completed per protocol and very serious imprecision as demonstrated by a low number of subjects (n = 40). The one retrospective cohort study
(Watnick et al, 2016) was assessed to have very serious imprecision as demonstrated by low number of events (n = 164).
If you have questions regarding this Specific Care Question – please contact evidencebasedpractice@cmh.edu
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Relapse of Symptoms with 2 Days of Dexamethasone vs. 5-6 Days of Prednisolone.
Three studies (Normansell et al., 2016; Paniagua et al., 2017; Volk et al., 2019) measured the relapse in symptoms of an asthma exacerbation within 14
days of the initial exacerbation, (n = 1,342). For the one systematic review (Normansell et al., 2016), using two of the pediatric studies (Greenberg et al.,
2008; Qureshi et al., 2001) and the single RCT (Paniagua et al., 2017) met the criteria for review, (n = 1,279), the OR = 1.65, 95% CI [.85, 3.19], p =
.14, indicated the intervention of two day dosing of dexamethasone was not different to the comparator of five to six day dosing of prednisolone (see Figure
5 & Table 2). The one cohort study (Volk et al., 2019), (n = 63), the OR = .33, 95% CI [.02, 7.13], p = .48, indicated the intervention of two-day dosing of
dexamethasone was not different to five-to-six-day dosing of prednisolone (see Figure 6 & Table 2).
Certainty of the Evidence for Relapse of Symptoms with 2 Days of Dexamethasone vs. 5-6 Days of Prednisolone. The certainty of the body
of evidence was low for the one systematic review and one RCT but very low for the observational study. The body of evidence for the systematic
review (Normansell et al., 2016) and the RCT (Paniagua et al., 2017), was assessed to have serious risk of bias due to study participants and study
personnel not blinded causing concern for performance bias. The observational study (Volk et al., 2019) was assessed to have very serious imprecision
due to small number of events and subjects.
Relapse of Symptoms with 2 Doses of Dexamethasone vs. 5 Days of Prednisolone initiated after hospital arrival.
One study (Hermani et al., 2021) measured the relapse in symptoms of an asthma exacerbation within 10 days of the initial exacerbation, (n= 961). For
the outcome of relapse of symptoms, the OR = 6.20, 95% CI [0.37, 103.50], p = .20 indicated the intervention of two days of dexamethasone was not
different compared to five days of prednisolone initiated after hospital arrival (see Table 3).
Certainty of the Evidence for Relapse of Symptoms with 2 Doses of Dexamethasone vs. 5 days of Prednisolone initiated after hospital
arrival. The certainty of the body of evidence was very low. The body of evidence for the one observational study (Hermani et al., 2021) was assessed
to have serious imprecision due to a low number of events and subjects. As only one study (Hermani et al., 2021) was identified to answer this
question inconsistency could not be assessed.
Relapse of Symptoms with 1-3 doses of Dexamethasone vs. 1-3 doses of Prednisolone before hospital arrival.
One study (Hermani et al., 2021) measured the relapse in symptoms of an asthma exacerbation within 10 days of the initial exacerbation, (n = 449). For
the outcome of relapse of symptoms, the OR = .76 95% CI [.14, 3.94], p = .74 indicated the intervention of one to three doses of dexamethasone was not
different than one to three doses of prednisolone provided prior to hospital arrival in decreasing relapse of asthma symptoms (see Table 4).
Certainty of the Evidence for Relapse of Symptoms with 1-3 doses of Dexamethasone vs. 1-3 doses of Prednisolone before hospital
arrival. The certainty of the body of evidence was very low. The body of evidence for the one observational study (Hermani et al., 2021) was assessed
to imprecision due to low number of events. As only one study (Hermani et al. 2021) was identified to answer this question, inconsistency could not be
assessed.
Identification of Studies
Search Strategy and Results (see Figure 1)
"Status Asthmaticus"[Mesh] OR "Asthma/drug therapy"[Mesh] OR "asthma exacerbation*") AND ("Dexamethasone/administration and
dosage"[Mesh] OR "Prednisolone/administration and dosage"[Mesh] OR "Prednisone/administration and dosage"[Mesh]) AND (child OR children OR
pediatr* OR paediatr* OR infant OR adolescence
Records identified through database searching n = 41
Additional records identified through other sources n = 1
Studies Included in this Review
Citation

Study Type
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*Elkharwili et al., 2020
RCT
Hermani et al., 2021
Cohort
*Kirkland et al., 2018
SR
* Normansell et al., 2016
SR
*Paniagua et al., 2017
RCT
Volk et al., 2019
Cohort
Watnick et al., 2016
Cohort
References marked with an asterisk indicate studies included in the meta-analysis
Studies Not Included in this Review with Exclusion Rationale
Citation
SR Bravo-Soto et al., 2017
SR Kirkland et al., 2019
SR Meyer et al., 2014

Reason for exclusion
In Spanish language
Articles of interest are included in two of the included SR
Articles of interest are included in in Kirkland et al. (2018) SR

Methods Used for Appraisal and Synthesis
aThe GRADEpro Guideline Development Tool (GDT) is the tool used to create the Summary of Findings table(s) for this analysis.
bRayyan is a web-based software used for the initial screening of titles and / or abstracts for this analysis (Ouzzani, Hammady, Fedorowicz & Elmagarmid,
2017).
cReview Manager (Higgins & Green, 2011) is a Cochrane Collaborative computer program used to assess the study characteristics as well as the risk of bias
and create the forest plots found in this analysis.
dThe Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram depicts the process in which literature is searched,
screened, and eligibility criteria is applied (Moher, Liberati, Tetzlaff, & Altman, 2009).
References to Appraisal and Synthesis Methods
aGRADEpro GDT: GRADEpro Guideline Development Tool (2015). McMaster University, (developed by Evidence Prime, Inc.). [Software]. Available
from gradepro.org.
bOuzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016). Rayyan-a web and mobile app for systematic reviews. Systematic Reviews, 5(1),
210. doi:10.1186/s13643-016-0384-4
aHiggins, J. P. T., & Green, S. e. (2011). Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011] (Version 5.1.0 ed.): The
Cochrane Collaboration, 2011.
dMoher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA
Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 For more information, visit www.prisma-statement.org.
Question Originator
A.Nedved, MD, E. Scott, DO, and C. Seguin, MD
Medical Librarian Responsible for the Search Strategy
K. Swaggart, MLIS, AHIP
EBP Team or EBP Scholar’s Responsible for Analyzing the Literature
J. A. Bartlett, PhD, RN
J. Dusin, MS, RD, LD, CPHQ
B. Hunter, RN, BSN, CPN
J. Wierson, RN, BSN, MBA, CCRC
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EBP Medical Director Responsible for Reviewing this Document
K. Berg, MD, FAAP
EBP Team Member Responsible for Reviewing, Synthesizing, and Developing this Document
A. Melanson, OTD, OTR/L
Acronyms Used in this Document
Acronym
Explanation
AGREE II
Appraisal of Guidelines Research and Evaluation II
CAT
Critically Appraised Topic
EBP
Evidence Based Practice
ED
Emergency Department
PRISMA
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
Statistical Acronyms Used in this Document
Statistical Acronym
Explanation
CI
Confidence Interval
I2
Heterogeneity test
M or 𝑋𝑋�
Mean
n
Number of cases in a subsample
N
Total number in sample
OR
Odds Ratio
P or p
Probability of success in a binary trial
RCT
Randomized controlled trial
RR
Relative risk
SD
Standard deviation
SE
Standard error
SR
Systematic Review
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Figure 1

Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA)d

If you have questions regarding this Specific Care Question – please contact evidencebasedpractice@cmh.edu

Date Finalized: 07/06/2022
22
Summary of Findings Table
Table 1

Summary of Findings Tablea: Relapse of Symptoms 1 Day Dexamethasone vs. 3-5 Days Prednisolone
Certainty assessment

Summary of findings

Study event rates (%)
Overall
Relative
Participants
Risk of
Publication certainty
effect
With
5-day
With
1-2
doses
(studies)
Inconsistency Indirectness Imprecision
bias
bias
of
(95%
course of
of
Follow-up
evidence prednisolone dexamethasone
CI)

Anticipated absolute effects
Risk with 5day course of
prednisolone

Risk difference
with 1-2 doses
of
dexamethasone

Relapse of symptoms (1 day Dexamethasone vs. 3-5 days Prednisolone)
615
(6 RCTs)

seriousa

not serious

not serious

seriousb

none

⨁⨁◯◯
Low

19/299
(6.4%)

16/316 (5.1%)

OR 0.74
(0.32 to
1.69)

64 per 1,000

16 fewer per
1,000
(from 42 fewer
to 39 more)

20

20

MD =
3.00
(-14.67,
20.67)

The mean
relapse of
symptoms (1
day
Dexamethasone
vs. 3-5 days
Prednisolone)
was 0

MD 3 higher
(14.67 lower to
20.67 higher)

143/7130
(2.0%)

21/1639 (1.3%)

OR 0.63
(0.40 to
1.01)

20 per 1,000

7 fewer per
1,000
(from 12 fewer
to 0 fewer)

Relapse of symptoms (1 day Dexamethasone vs. 3-5 days Prednisolone)
40
(1 RCT)

seriousd

not serious

not serious

very seriousc

none

⨁◯◯◯
Very low

Relapse of symptoms (1 day Dexamethasone vs. 3-5 days Prednisolone)
8769
not
(1
serious
observational
study)

not serious

not serious

seriousb

none

⨁⨁◯◯
Low

Notes:
a. both study participants and study personnel not blinded, concerns for performance bias
b. low number of events
c. low number of subjects
d. randomization not completed as stated and data analysis followed per protocol analysis
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Table 2

Summary of Findings Tablea: Relapse of symptoms 2 days Dexamethasone vs. 5-6 days Prednisolone
Certainty assessment

Summary of findings

Study event rates (%)
Overall
Relative
Participants
Risk of
Publication certainty
effect
With
5-day
With
1-2
doses
(studies)
Inconsistency Indirectness Imprecision
bias
bias
of
(95%
course of
of
Follow-up
evidence prednisolone dexamethasone
CI)

Anticipated absolute effects
Risk with 5Risk difference
day course
with 1-2 doses
of
of
prednisolone dexamethasone

Relapse of symptoms (2 days Dexamethasone vs. 5-6 days Prednisolone)
1279
(3 RCTs)

seriousa

not serious

not serious

seriousb

none

⨁⨁◯◯
Low

15/675
(2.2%)

25/604 (4.1%)

OR 1.65
(0.85 to
3.19)

22 per 1,000

14 more per
1,000
(from 3 fewer to
45 more)

2/40 (5.0%)

0/23 (0.0%)

OR 0.33
(0.02 to
7.13)

50 per 1,000

33 fewer per
1,000
(from 49 fewer to
223 more)

Relapse of symptoms (2 days Dexamethasone vs. 5-6 days Prednisolone)
63
not
(1
serious
observational
study)

not serious

not serious

seriousc

none

⨁◯◯◯
Very low

Notes:
a. both study participants and study personnel not blinded, concerns for performance bias
b. low number of events
c. Low number of events and subjects

Table 3

Summary of Findings Tablea: Relapse of symptoms 2 days Dexamethasone vs. 5 days Prednisolone initiated after
hospital arrival hospitalized
Certainty assessment
Participants
(studies)
Follow-up

Risk
of
bias

Summary of findings

Study event rates (%)
Overall
Relative
Publication certainty
effect
With 5-day
With 1-2 doses
Inconsistency Indirectness Imprecision
bias
of
(95%
course of
of
evidence prednisolone dexamethasone
CI)

Anticipated absolute effects
Risk with 5day course
of
prednisolone

Risk difference
with 1-2 doses
of
dexamethasone

0 per 1,000

0 fewer per
1,000
(from 0 fewer to 0
fewer)

Relapse of symptoms (2 doses Dexamethasone vs. 5 doses Prednisolone during hospitalization)
961
not
(1
serious
observational
study)

not serious

not serious

seriousa

none

⨁◯◯◯
Very low

0/135 (0.0%)

18/826 (2.2%)

OR 6.20
(0.37 to
103.50)

Notes:
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a. Low number of events and subjects

Table 4

Summary of Findings Tablea: Relapse of symptoms 1-3 doses Dexamethasone vs. 1-3 doses Prednisolone before
hospital arrival
Certainty assessment
Participants
(studies)
Follow-up

Risk
of
bias

Summary of findings

Study event rates (%)
Overall
Relative
Publication certainty
effect
With 5-day
With 1-2 doses
Inconsistency Indirectness Imprecision
bias
of
(95%
course of
of
evidence prednisolone dexamethasone
CI)

Anticipated absolute effects
Risk with 5day course
of
prednisolone

Risk difference
with 1-2 doses
of
dexamethasone

17 per 1,000

4 fewer per
1,000
(from 15 fewer to
47 more)

Relapse of symptoms (1-3 doses Dexamethasone vs. 1-3 doses Prednisolone before hospital arrival)
449
not
(1
serious
observational
study)

not serious

not serious

seriousa

none

⨁◯◯◯
Very low

5/294 (1.7%)

2/155 (1.3%)

OR 0.76
(0.14 to
3.94)

Notes:
a. Low number of events and subjects
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Meta-analysis
Figure 2

Comparison: 1 day Dexamethasone versus 3-5 days Prednisolone, Outcome: Relapse of symptoms

Figure 3

Comparison: 1 day Dexamethasone versus 3-5 days Prednisolone, Outcome: Relapse of symptoms

If you have questions regarding this Specific Care Question – please contact evidencebasedpractice@cmh.edu

Date Finalized: 07/06/2022
26

Figure 4

Comparison: 1 day Dexamethasone versus 3-5 days Prednisolone, Outcome: Relapse of symptoms

Figure 5

Comparison: 2-day Dexamethasone versus 5-6 days Prednisolone, Outcome: Relapse of symptoms
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Figure 6

Comparison: 2-day Dexamethasone versus 5-6 days Prednisolone, Outcome: Relapse of symptoms
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Characteristics of Intervention Studies
Elkharwili, 2020
Methods

Randomized Control Trial

Participants

Participants: Children with acute exacerbation of asthma
Setting: Hospital (Tanta University Hospital, Egypt, March 2016 - October 2017)
Randomized into study: N = 94
• Group 1, 0.3 mg/kg oral dexamethasone for one day: n = 35
• Group 2, 0.6 mg/kg of oral dexamethasone for two days: n = 32
• Group 3, 1.5 mg/kg oral prednisolone: n = 27
Completed Study Treatment: N = 81
• Group 1: n = 29
• Group 2: n = 29
• Group 3: n = 23
Completed Follow-up Phase of Study: N = 60
• Group 1: n = 20
• Group 2: n = 20
• Group 3: n = 20
Gender, males (as defined by researchers):
• Group 1: n = 40%
• Group 2: n = 50%
• Group 3: n = 55%
Race / ethnicity or nationality:
• The authors did not identify race or ethnicity of the participants.
Age, mean in years (SD):
• Group 1: 5.93 (2.37)
• Group 2: 6.52 (2.64)
• Group 3: 6.15 (2.75)
Inclusion Criteria:
• children with a history of bronchial asthma,
• those that presented with an asthma exacerbation, which was defined as a decrease in expiratory airflow
• that could be documented and quantified by simple measurement of lung function (spirometry or peak expiratory
flow (PEF))
• age 2 - 11 years
If you have questions regarding this Specific Care Question – please contact evidencebasedpractice@cmh.edu
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• male or female
Exclusion Criteria:
• children aged 11 years
• children with intubation history for previous asthma exacerbations
• children with active varicella or herpes simplex infection in the past 3 weeks
• children with documented concurrent infection with respiratory syncytial virus
• use of oral or intravenous corticosteroids in the previous 4 weeks
• concurrent stridor
• known patients with tuberculosis
• presence of other significant comorbidities such as: cardiac, immune, liver, endocrine, neurological and psychiatric
disorders
Power Analysis: Analysis at a p value of 0.05 and a power of 80% showed that a total sample size of 78 patients
distributed as 1:1:1 in the three groups was necessary. The level of significance was set at a p value < 0.05, while p values
of 0.01 and 0.001 were considered highly significant.
Interventions

Group 1: single dose of 0.3 mg/kg oral dexamethasone, with a maximum dose of 12mg/day for 1 day and continued with a
placebo for the other 4 days
Group 2: 0.6 mg/kg of oral dexamethasone, with a maximum dose of 16 mg/day in three divided doses for two
consecutive days and continued with a placebo for the other 3 days
Group 3: 1.5 mg/kg oral prednisolone per day for 5 days with a maximum dose of 60 mg in three divided doses

Outcomes

Primary outcome(s):
• Change in physical examination, Pediatric Respiratory Assessment Measure (PRAM) score*, the Modified Pulmonary
Index Score (MPIS)*, pulmonary function tests*, saturated oxygen, blood eosinophilic count and serum
immunoglobulin E after 5 days of taking the corticosteroids
Secondary outcome:
• Vomiting, gastrointestinal tract (GIT) cramps and relapse rate were recorded as secondary outcomes of the study
Safety Outcome:
• Relapse Rate*
*Outcomes of interest for the CPG Team
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Notes

• Due to protocol deviations and participants lost to follow-up, the authors did not meet the sample size calculated to
determine significance

• There was no statistically significant difference in weight gain and blood sugar before and after 5 days of treatment
within the same group

• After 5 days of treatment, pairwise comparison showed a significant difference in blood sugar level only between
group II and group III (p=0.004)

• After 5 days of treatment, comparison of the participants showed that there was a highly statistical difference in
MPIS, oxygen need, duration of hospital admission and PRAM within the three groups (p<0.001).

• After 30 days, ATAZ Asthma Therapy Assessment Questionnaire (ATAQ) showed no significant differences among
the three studied groups for missed days of school

Risk of bias table
Bias

Judgement

Support for judgement

Random sequence generation
(selection bias)

High risk

Allocation concealment
(selection bias)

Unclear risk

Blinding of participants and
personnel (performance bias)

Unclear risk

Blinding of outcome
assessment (detection bias)

Unclear risk

Incomplete outcome data
(attrition bias)

High risk

The authors identify in Table 1 that patients with protocol deviations (Group I: 6, Group II: 3, Group III:
4) were not counted as completing study. In Table 5 the authors only include in the final analysis the data
from only the participants completing the follow-up phase therefore data is missing from 21 additional
participants (Group i: 9, Group II: 9 and Group III: 3). With the removal of this data the authors did not
meet the sample size needed to detect significance between the different groups.

Selective reporting (reporting
bias)

Low risk

The only thing not noted in the outcomes table was the saturation oxygen, but there were other
parameters captured such as PEF (%) and FEV1/FVC (%) so noted as low risk

Other bias

Unclear risk

There may be a risk of bias, but there is insufficient information to assess whether an important risk of
bias exists.

Article states that 94 eligible patients were assigned and randomized in a 1:1:1 ratio into three groups. It
does not specify as to how the randomization was generated. Although this is stated, it shows that the
following were the initial group allocations: Group I: 35 patients, Group II: 32 patients and Group III: 27
patients which does not prove that a 1:1:1 ratio was used.
Insufficient information to permit judgment of low or high risk
Article states that it was a double-blind clinical trial but doesn't describe any further information regarding
blinding methods
Insufficient information to permit judgment of low risk or high risk

If you have questions regarding this Specific Care Question – please contact evidencebasedpractice@cmh.edu

Date Finalized: 07/06/2022
31

Hemani, 2021
Methods

Multisite Retrospective Cohort

Participants

Participants: Patients 3 to 21 years admitted between January 1, 2013, and December 31, 2017, with primary discharge
diagnosis, IDC 9 and ICD 10, of asthma exacerbation or status asthmaticus
Setting: Atlanta, USA, Tertiary Children's Hospital System
Number enrolled into study: N = 1410
• Group 1, Dexamethasone (DEX) Initiated After Hospital Arrival: n = 826
• Group 2, Prednisone/prednisolone (PRED) Initiated After Hospital Arrival: n = 135
• Group 3, Dexamethasone (DEX) Before Hospital Arrival: n = 155
• Group 4, Prednisone/prednisolone (PRED) Before Hospital Arrival: n = 294
Gender, males:
• Group 1:
• Group 2:
• Group 3:
• Group 4:

n
n
n
n

=
=
=
=

531 (64.3%)
77 (57%)
96 (62%)
192 (65.3%)

Race (reported numbers do not reach total enrolled, but reported percentages equal 100):
• Black
o Group 1: n = 562 (72.3%)
o Group 2: n = 76 (58%)
o Group 3: n = 83 (55%)
o Group 4: n = 152 (53.3%)
• White
o Group 1: n = 126 (16.2%)
o Group 2: n = 33 (35%)
o Group 3: n = 43 (29%)
o Group 4: n = 76 (26.7%)
• Asian
o Group 1: n = 17 (2.2%)
o Group 2: n = 1 (1%)
o Group 3: n = 6 (4%)
o Group 4: n = 8 (2.8%)
• Other
o Group 1: n = 72 (9.3%)
o Group 2: n = 20 (15%)
o Group 3: n = 18 (12%)
o Group 4: n = 49 (17.2%)
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Ethnicity:
• Hispanic or Latino
o Group 1: n =
o Group 2: n =
o Group 3: n =
o Group 4: n =
• Non- Hispanic or Latino
o Group 1: n =
o Group 2: n =
o Group 3: n =
o Group 4: n =

111 (13.5%)
26 (19%)
19 (12%)
31 (10.6%)
714
109
136
262

(86.6%)
(81%)
(88%)
(89.4%)

Age, mean in years, (SD):
• Group 1: 6.79 (3.3)
• Group 2: 6.54 (3.1)
• Group 3: 6.49 (3.3)
• Group 4: 6.87 (3.1)
Inclusion Criteria:
• Age of 3 to 21 years
• Receiving monotherapy with DEX or PRED
• Multiple asthma-related hospital visits within a 10-day period only the first encounter was captured
Exclusion Criteria:
• Less than 3 years of age
• Receiving an unspecified oral steroid or combination of DEX and PRED during acute illness
• Missing information about steroid administration prior to admission
• Methyl prednisone administration during acute illness
• Steroid administration in the prior 2 weeks or receiving a prolonged steroid course
• Initial PICU admission
• Concurrent diagnosis of bronchiolitis, pneumonia, or croup
• Use of Bi-level positive airway pressure
• Supplemental therapies in the Emergency Department (e.g., antibiotics, oseltamivir, heliox, terbutaline, racemic
epinephrine, hypertonic saline, chest physiotherapy, and budesonide)
• Pulmonary or cardiac comorbidities, sickle cell disease, down syndrome, or immunosuppression
• Hospital admissions with paper chart documentation
• Left against medical advice or readmission
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Covariates Identified:
• Albuterol administration prior to hospital arrival
Interventions

Both: Received a clinical respiratory score; received albuterol; may receive ipratropium, magnesium, and supplemental
oxygen
• Group 1: Received an average dose of DEX 0.5 mg/kg per day for a median of 2 days while hospitalized
• Group 2: Received an average dose of PRED 1.8 mg/kg per day for a median of 2 days while hospitalized
• Group 3: Received an average dose of DEX 0.5 mg/kg per day for a median of 1 day while hospitalized
• Group 4: Received an average dose of PRED 1.8 mg/kg per day for a median of 2 days while hospitalized

Outcomes

Primary outcome:
• Length of stay (LOS)*
Secondary outcomes:
• PICU transfer during initial hospitalization*
• Readmission within 10 days after hospital discharge*
Safety outcome:
• Not reported
*Outcomes of interest to the CMH CPG /CAT development team

Notes

Limitations:
• Retrospective study, susceptible to adjustment items
• Majority of patients classified as mild intermittent or mild persistent asthma
• Exclusion criteria prevented severe asthma exacerbation patient inclusion in study
• Previous inhaled corticosteroid uses not included
• Steroid adherence after discharge not tracked
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Kirkland, 2018
Methods

Systematic Review (meta-analysis)

Objective

To examine the effectiveness and safety of a single dose of intramuscular (IM) corticosteroids provided prior to discharge
compared to a short course of oral corticosteroids in the treatment of acute asthma patients discharged from an ED or
equivalent acute care setting.

Methods

Criteria for considering studies for this review
• Types of studies: RCTs or controlled clinical trials
• Participants: Adults and pediatric patients presenting with acute asthma to an ED or acute care setting.
• Target Condition(s): Acute asthma exacerbation
Search methods for identification of studies
• Electronic databases searched: Cochrane Airways Group Register of Trials and databases including
Medline, Embase, EBM ALL, Global Health, International Pharmaceutical Abstracts, CINAHL,
SCOPUS, ProQuest Dissertations and Theses Global, and LILACS.
• Search strategy employed:
o *Secondary Prevention; Acute Disease; Administration, Oral; Adrenal Cortex Hormones
[*administration & dosage]; Anti-Asthmatic Agents [*administration & dosage]; Asthma [drug
therapy] [*prevention & control]; Betamethasone [administration & dosage]; Dexamethasone
[administration & dosage]; Emergency Service, Hospital; Injections, Intramuscular;
Methylprednisolone [administration & dosage]; Patient Discharge; Prednisolone [administration &
dosage]; Prednisone [administration & dosage]; Randomized Controlled Trials as Topic;
Recurrence; Triamcinolone [administration & dosage]
o Included full text, abstracts, and unpublished data in search criteria.
•
Searching other resources (such as reference list): Reference lists of all primary studies and review
articles were checked for additional references. Relevant manufacturers’ web sites were also searched for
additional study information.
Data collection and analysis
• Inclusion criteria:
o RCTs and controlled clinical trials
o Studies with acute exacerbation of asthma as primary reason for presentation to ED with no other
co-existing complications
o Asthma diagnosis had to be made either using international/national clinical guidelines or
spirometric criteria or both
• Exclusion criteria:
o Studies that focused on corticosteroid treatment in hospitalized patients
• Population: Adult and pediatric patients with uncomplicated exacerbation of asthma
• Setting: Hospital ED or equivalent acute care setting
• Study Design: Systematic review and meta-analysis
•
Data collection process: Two independent reviewers assessed study eligibility and study quality.
Disagreements were resolved by a third party and assessed the risk of bias using the Cochrane Risk of Bias
toll.
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Results

•

Assessment of the certainty of the evidence: Quality of the evidence was measured/assessed using
GRADE.

•

Data Synthesis (what statistical plan do the authors establish a priori):
o Random effects model used and performed a sensitivity analysis with a fixed-effect model.
o Heterogeneity: I2 statistic used to measure heterogeneity. If substantial heterogeneity was
identified, it was reported, and possible causes were explored using a prespecified subgroup
analysis (see subgroup analysis below):
 Children (zero to 18 years of age) versus adults (18 years of age and older) to examine any
potential age-specific treatment effects of IM or oral corticosteroids.
 Relapse occurring within 10 days and over 10 days post-discharge.
 Low versus moderate versus high exacerbation severity based on the pulmonary function
taken at the time of the participant's presentation to the ED, prior to treatment with a
bronchodilator.
 Co-interventions received (ICS versus ICS corticosteroids/long-acting beta2-agonists (LABA).
o
Sensitivity analysis carried out by removing the following types of studies from primary
outcome analyses:
 Studies that we consider to be at high risk of bias based on the criteria outlined in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).
 Studies in which the duration of oral corticosteroid treatment was less than five days.
 The results from fixed-effect models were compared with the random-effects models for the
main outcome.
 Studies in which supplemental corticosteroids were provided to the patients in the ED as a cointervention

Study Selection (actual results/data)
Number of articles identified: N = 912
Full-text articles assessed for eligibility: n = 20
o Studies included in qualitative synthesis: n = 9
Synthesis of quality of evidence (strength of evidence): Using GRADE, the overall certainty of the
evidence was assessed per outcome ranging from low to moderate with the following results per outcome:
•
Primary outcomes of relapse as well as relapse after 10 days was rated as low quality due to overall unclear
to high risk of bias of the studies and imprecision due to wide confidence intervals including both
benefit, harm and no effect. The subgroup analysis for relapse was rated at low quality due to the low
number of available patients and wide confidence intervals.
•
Outcome for adverse events also ranked at low quality due to overall unclear to high risk of bias of the
included studies and imprecision due to few events.
•
Outcome of symptom persistence and 24-hour beta2-agonists use ranked as low quality due to the overall
unclear to high risk of bias of the included studies as well as few events.
• Outcome of peak expiratory flow ranked as moderate quality due ot imprecision of the results.
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Synthesis of quantitative evidence: (pediatric patients only)
• Overall Effect Size: Intramuscular versus oral corticosteroids, Outcome: Relapse
 Odd Ratio: .78
 CI: 95% CI [.38, 1.57], p = .49
 Heterogeneity
• I2=0%

•

•
•

Discussion

Summary of evidence
•
Systemic corticosteroids were found to be an effective treatment in decreasing relapse of symptoms for
acute asthma exacerbation for ED or equivalent acute care settings and assists with prevention of
admission however, the optimal route of dosing and administration is unclear.
Limitations

•
•
•
•
•
•

Funding

Overall Effect Size: Intramuscular versus oral corticosteroids, Outcome: Relapse intention to treat
 Odds Ratio: .78
 CI: 95% CI [0.38, 1.57], p = .48
 Heterogeneity
• I2=0%
Overall Effect Size: Intramuscular versus oral corticosteroids, Outcome: Relapse within 10 days
 Odds Ratio: .75
 CI: 95% CI [0.28, 2.0], p = .57
Overall Effect Size: Intramuscular versus oral corticosteroids, Outcome: Relapse over 10 days
 Odds Ratio: .78
 CI: 95% CI [0.38, 1.57, p = .48
 Heterogeneity
• I2=0%

Lack of reporting out of data on secondary outcomes significantly limited the number of studies that could
be used for the meta-analysis and impacted the authors’ ability to draw meaningful conclusions or
recommendations towards the overall effectiveness of IM corticosteroids.
Only four pediatric studies met the inclusion criteria.
The effectiveness of the corticosteroids results may have been impacted by the age of the children enrolled
in the study meaning, younger children may not respond to the corticosteroids due to fewer airway
eosinophils.
Co-interventions were poorly reported in studies reviewed and it is likely that some of the agents used may
no longer be used.
Lack of reporting on the use of the ICS and ICS/LABA agents limited the review on its ability to estimate
the impact of these agents on the efficacy of IM or oral corticosteroids.
Dosing of corticosteroids was not a criterion used for inclusion and thus, no conclusion was drawn on the
impact of dosing completed.

The National Institute for Health Research (NIHR) supported this project, via Cochrane Infrastructure funding to the
Cochrane Airways Group.
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Normansell, 2016
Methods

Systematic Review (meta-analysis)

Objective

To assess the efficacy and safety of any dose or duration of oral steroids versus any other dose or duration of oral steroids
for adults and children with asthma exacerbation.

Methods

Criteria for considering studies for this review
• Types of studies:
o RCTs
•
Participants:
o Adults
o Children
• Target Condition(s):
o Acute Asthma Attack
Search methods for identification of studies
• Electronic databases searched: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE,
EMBASE, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), the Allied and Complementary
Medicine Database (Alangari et al.) and PsycINFO, and by handsearching respiratory journals and meeting
abstracts
• Search strategy employed: Mesh terms (see study for full list)
• Searching other resources: Handsearching of respiratory journals and meeting abstracts
Data collection and analysis
• Inclusion criteria:
o Randomized controlled trials (RCTs), irrespective of blinding or duration, that evaluated one dose or
duration of oral steroid versus any other dose or duration, for management of asthma exacerbations.
o Both adults and children with asthma of any severity, in which investigators analyzed adults and children
separately.
o Other co-intervention in the management of an asthma exacerbation, provided it was not part of
the randomized treatment.
• Exclusion criteria:
o Wrong comparator
o Wrong intervention
o Not randomized
• Population:
o Adults and children with acute exacerbation of asthma
• Setting:
o Inpatient
o Emergency department
• Study Design:
o Systematic review and meta-analysis
• Data collection process:
o Data collection form designed by two of the investigators
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•
•

Results

Assessment of the certainty of the evidence:
o GRADE
Data Synthesis (what statistical plan do the authors establish a priori):
o Overall Effect Size (just state what is being used in the study)
 OR
 RD
 CI
o Heterogeneity

Cochran’s Q statistic

I2 statistic

Study Selection (actual results/data)
Number of articles identified: N = 1406
Full-text articles assessed for eligibility: n = 71
o Studies included in qualitative synthesis: n = 18
Synthesis of quality of evidence (strength of evidence):
• Low to very low certainty
Synthesis of quantitative evidence:
• Prednisolone vs dexamethasone, outcome: Admission during follow-up
o OR = .09 (-0.07, 0.26), p-value = .9
o n = 3 studies (985 patients)
o I2 = 0%
• Prednisolone vs dexamethasone, outcome: Re-admission during follow-up
o OR = .44 (0.15, 1.33), p-value = .14
o n = 3 studies (985 patients)
o I2 = 0%
• Prednisolone vs dexamethasone, outcome: Asthma symptoms: Pulmonary Index Score
o MD = -.1 (0.45, 0.25), p-value = .58
o n = 1 study (100 patients)
• Prednisolone vs dexamethasone, outcome: Asthma symptoms: Patient Self-Assessment Score
o MD = .1 (-0.67, 0.69), p-value = .98
o n = 1 study (100 patients)
• Prednisolone vs dexamethasone, outcome: Asthma symptoms: Pediatric Respiratory Assessment Measure
o MD = 0 (-0.36, 0.36),
o n = 1 study (218 patients)
• Prednisolone vs dexamethasone, outcome: new exacerbation during follow-up period: unscheduled visit to
healthcare provider
o OR = .85 (0.54, 1.34), p-value = .48
o n = 4 study (981 patients)
o I2 = 0%
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•

Discussion

Funding

Prednisolone vs dexamethasone, outcome: new exacerbation during follow-up period: oral corticosteroids
prescribed
o OR = .29 (0.1, 0.81)
o n = 1 study (242 patients)

Summary of evidence
• There was difficulty combining the results of studies in a useful way because investigators used a variety of doses
and durations of steroids and measured their results in diverse ways. Also, events such as hospital admissions and
serious side effects happened very rarely in these studies, making it difficult to tell whether longer or shorter
courses or higher or lower doses are better or safer, or if prednisolone is generally better or worse than
dexamethasone. Some studies were old and did not use steroid doses or durations used by medical practitioners
today.
Limitations
•
Evidence presented in the review is generally considered to be of low or very low certainty, which means there is a
great amount of uncertainty of whether the results are accurate, mostly because the authors could not combine
many studies. Some studies did not clearly explain how trial organizers decided which people would receive which
dose of steroids, and in some studies, both participants and trial organizers knew which dose they were getting.
Funding
•
Cochrane Collaborative
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Paniagua, 2017
Methods

Randomized Control Trial

Participants

Participants: Children with asthma exacerbation who presented to the emergency department (ED) Sept 2014-October
2015
Setting: Acute care teaching tertiary hospital, Spain (Basque Country)
Randomized into study: N = 590
• Group 1: Dexamethasone, n = 294
• Group 2: Prednisolone, n = 296
Completed Study: N = 557
• Group 1: n = 281
• Group 2: n = 276
Gender, males: mean, (%)
• Group 1: n = 169 (60.1%)
• Group 2: n = 166 (60.1%)
Race / ethnicity or nationality:
• Not reported
Age, years (mean) (Einarsdottir et al.):
• Group 1: 4.7 (3.4)
• Group 2: 4.5 (3.4)
Inclusion Criteria:
• Aged 1-14 years
• History of previous diagnosis of asthma or at least 2 previous episodes responsive wheeze or first wheezing episode
in a child > 2 years with history of atopy
• Respiratory symptomso Acute cough, shortness of breath, tachypnea attributed to bronchospasm (wheezing, prolong expiration),
increased work of breathing, and/or increased bronchodilator requirements from baseline
Exclusion Criteria:
• Other airway pathology
• Other diseases that require hospitalization for safety
• Children with life-threatening asthma exacerbation
• Use of oral or parenteral corticosteroids in the past 4 weeks
Power Analysis: Sample size calculation was based on a Pediatric Asthma Control Tool (PACT) score at day seven for the
dexamethasone group would not be more than 6% greater than the prednisolone group score; a sample size of at least 556
subjects was required to detect a difference.
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Interventions

Both groups: received the first 2-3 β2-agonist treatments at 20-minute intervals with the addition
of ipratropium bromide prescribed per attending provider.
•
Group 1: Dexamethasone*, oral, (1 mg/ml), 0.6 mg/kg, maximum 12 mg, one dose received in the ED, a second
dose was administered 24 hours later.
•
Group 2: Prednisone/prednisolone*, oral, 1.5 mg/kg, maximum 60 mg, one dose in the ED, followed by 1 mg/kg/d,
maximum 60 mg, twice daily on days 2 - 5. Choice of liquid or tablet formulate was based on the subject’s age.
o *If either treatment was vomited within 30 minutes, the dose was re-administered.
Subjects were contacted by phone on day 7 and 15 in which PACT questionnaire and the asthma related quality of
life (ARQoL) instrument was completed. Both instruments are validated.

Outcomes

Primary outcome(s):
• Percent of subjects with symptoms at 7 days [PACT score] * and their quality of life score [ARQoL score].
Secondary outcome(s):
• Vomiting
• Adherence to treatment
• Parent satisfaction
• Admission rate*
• Unscheduled returns to ED*
• Hospital re-admissions
• Visits to Primary Care Provider
• School and work absenteeism
Safety outcome(s):
• Not reported
*Outcomes of interest to the CMH CPG team

Notes

Trial registered - clinicaltrialsregister.eu: 2013-003145-42, the registry states it is ongoing July 2, 2018,

Risk of bias table
Bias

Judgement

Random sequence generation
(selection bias)

Low risk

Allocation concealment
(selection bias)

Low risk

Blinding of participants and
personnel (performance bias)

High risk

Blinding of outcome
assessment (detection bias)

Unclear risk

Support for judgement
Statisticians performed the randomization
allocation concealment was maintained using sequentially numbered opaque envelopes containing a letter A
(experimental treatment) or B (conventional treatment), following the randomization list.
Open label, with subjective outcomes
Data managers and the statistical team were blinded but bias could have occurred during the interview with
family.
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Incomplete outcome data
(attrition bias)

Low risk

Selective reporting (reporting
bias)

Low risk

Other bias

High risk

Used a per-protocol analysis, met sample size needed to detect inferiority between interventions.
All outcomes were reported
Treating physician was permitted to exclude patients if time constraints made enrollment unfeasible.
The PACT tool used in a six-item inventory. References were found to the 10 and 3 item PACT, not the 6
item PACT. Self-reported response to both the PACT and the quality-of-life inventories.
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Volk, 2019
Methods

Retrospective Cohort

Participants

Participants: Pediatric patients with Asthma or wheezing,
Setting: Ambulatory Setting between August 2013 to July 2015
Number enrolled into study: N = 63
• Group 1, Prednisone: n = 40
• Group 2, Dexamethasone: n = 23
Gender, males (as defined by researchers):
• Group 1: n = 31 (78%)
• Group 2: n = 23 (78%)
Race / ethnicity or nationality (as defined by researchers):
• Group 1: Non-Hispanic n = 16 (40%)
• Group 1: Hispanic n = 24 (60%)
• Group 2: Non-Hispanic n = 6 (26%)
• Group 2: Hispanic n = 17 (74%)
Age, mean (years)
• Group 1: 6.4
• Group 2: 7.8
Inclusion Criteria:
• ≥ 3 years of age
• Primary visit diagnosis of “wheezing” (ICD9 786.07), “asthma unspecified type with exacerbation” (ICD9 493.92),
“asthma with status asthmaticus” (ICD9 493.91), or “cough variant asthma” (ICD9 493.82)
Exclusion Criteria:
• Received steroid treatment from an outside health facility within 1-week of presentation to the Center
Covariates Identified:
• Not reported
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Interventions

Both: inhaled ß-agonist treatment prior to corticosteroid with supplemental oxygen is oxygen saturations fall below 94%.
•
•

Outcomes

Group 1: Oral Prednisone-a single dose of weight-based prednisolone as either an oral tablet or liquid solution.
Additional daily single doses are prescribed and completed at home over 5 days.
Group 2: Oral Dexamethasone-single dose of a dissolvable oral tablet using a weight-based formula at the Center.
A second dose is prescribed and given within 24 hrs. (typically at home) to complete the 2-day course

Primary outcome(s):
• ED visits
• Hospital admissions
• Return clinic visits within 1 week for recurrent
• *Persistent symptoms
*Outcomes of interest to the CMH CPG development team

Notes

Results:
• The rates of hospital admissions, ED visits, and symptom follow-up were similar between the 2 groups (P > .05).
• The cost for a course of dexamethasone was US $1.28 versus US $16.20 for prednisolone. The average cost for an
asthma exacerbation office visit was US $79.89 compared with US $3113.28 for an ED visit.
Limitations:
• As the EMR was surveyed, errors may exist in coding and documentation
• Unable to determine the true illness severity as measured by the number of previous exacerbations and the dose or
duration of inhaled corticosteroids
• Call backs were not done to determine medication compliance or medication adverse effects
• Insurance claims from outside health facilities could not be tracked for 16% of patients, do not know if they were
treated for wheezing elsewhere

If you have questions regarding this Specific Care Question – please contact evidencebasedpractice@cmh.edu

Date Finalized: 07/06/2022
45

Watnick, 2016
Methods

Cohort

Participants

Participants: patients 3 to 17 years old with acute asthma exacerbations
Setting: urban tertiary care children's hospital ED
Number enrolled into study: N =13,518 (4,749 excluded because they did not receive corticosteroid)
number included in study: 8,769
•
Group 1, prednisone/prednisolone: n = 7130
•
Group 2, dexamethasone: n = 1639
Gender, males (as defined by researchers)-not described per study group but overall patients compared to
those with corticosteroids and relapse:
•
n = 8,281 (61%) (all patients with & without corticosteroid treatment)
•
n = 109 (60 %) (patients with relapse)
Race / ethnicity or nationality (as defined by researchers):
•
4,783 (35%) White (all patients with & without corticosteroid treatment) 63 (34%) White (patients with relapse)
•
7,701 (57%) Black (all patients with & without corticosteroid treatment) 108 (59%) Black (patients with relapse)
•
119 (1%) Asian (all patients with & without corticosteroid treatment) 1 (1%) Asian (patients with relapse)
•
36 (0%) American Indian or Alaskan (all patients with & without corticosteroid treatment) 0 (0%) American Indian
or Alaskan (patients with relapse)
•
1 (0%) Pacific Islander (all patients with & without corticosteroid treatment) 0 (0%) (patients with relapse)
•
878 (7%) unknown or declined (all patients with & without corticosteroid treatment) 11 (6%) (patients with
relapse)
Age, mean/median in months/years, (range/IQR
•
Group 1: 7 (4-10) (all patients with & without corticosteroid treatment)
•
Group 2: 7 (4-11) (patients with relapse)
Inclusion Criteria:
•
Patients 3 to 17 years old
•
Seen in ED, treated with systemic corticosteroids and subsequently discharged
•
Those that returned within 72 hours with continued asthma symptoms
Exclusion Criteria:
•
Patients in ED for asthma exacerbation not receiving corticosteroids or IV formulation of corticosteroids
•
For patients with multiple return trips to the ED within 72 hours, only the first return visit was analyzed.
Covariates Identified:
•
None identified
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Interventions

•
•

Group 1: oral prednisone or prednisolone-2 mg/kg for 3 to 5 days
Group 2: oral dexamethasone 0.6mg/kg given in a single dose

Outcomes

Primary outcome(s):
•
*Relapse rates of patients receiving oral dexamethasone with those receiving oral prednisone or prednisolone.
Secondary outcome(s):
•
None described
Safety outcome(s):
•
None
*Outcomes of interest to the CMH CPG development team

Notes

Results:
• Group 1: 143 cases of relapse of symptoms
• Group 2: 21 cases of relapse of symptoms
Limitations:
• Lack of information available on patient’s severity of asthma exacerbation
• Lack of information on detailed asthma characteristics, patient’s exposure to smoke, and flu vaccine status
• Potential loss of patients that would have qualified for the study inclusion, however, may have been classified
incorrectly from the International Classification of Diseases, nineth edition
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Evidence to Decision for Dexamethasone
Should 1-2 doses of dexamethasone vs. 5-day course of prednisolone be used for children greater than 2 years old with acute asthma
exacerbation?
POPULATION:

children greater than 2 years old with acute asthma exacerbation

INTERVENTION:

1-2 doses of dexamethasone

COMPARISON:

5-day course of prednisolone

MAIN OUTCOMES:

Relapse of symptoms (1 day Dexamethasone vs. 3-5 days Prednisolone); Relapse of symptoms (1 day Dexamethasone vs. 3-5
days Prednisolone); Relapse of symptoms (1 day Dexamethasone vs. 3-5 days Prednisolone); Relapse of symptoms (2 days
Dexamethasone vs. 5-6 days Prednisolone); Relapse of symptoms (2 days Dexamethasone vs. 5-6 days Prednisolone); Relapse of
symptoms (2 doses Dexamethasone vs. 5 doses Prednisolone during hospitalization); Relapse of symptoms (1-3 doses
Dexamethasone vs. 1-3 doses Prednisolone before hospital arrival);

ASSESSMENT
Problem
Is the problem a priority?
JUDGEMENT
○
○
○
●
○
○

No
Probably no
Probably yes
Yes
Varies
Don't know

RESEARCH EVIDENCE

ADDITIONAL CONSIDERATIONS

Since the last review of asthma exacerbations in pediatrics, there has
been an uptick in literature measuring the efficacy of 1-2 doses of
dexamethasone compared to a 5-day course of prednisolone.
Dexamethasone is less expensive with a long half-life compared to
prednisolone. In addition, prednisolone’s poor palatability can make
compliance with a five-day course challenging, especially with children.
Thus, the question becomes a priority if providers have an alternative
systemic corticosteroid that demonstrates similar recovery of symptoms
yet is both less expensive and requires fewer doses.

Desirable Effects
How substantial are the desirable anticipated effects?
JUDGEMENT
○
○
○
●
○
○

Trivial
Small
Moderate
Large
Varies
Don't know

RESEARCH EVIDENCE

ADDITIONAL CONSIDERATIONS

In review of all studies, the test for overall effect showed the
intervention (dexamethasone) and the control (prednisolone) were
effective and equivalent in reducing relapse of symptoms regardless of
dosing provided.

The desired anticipated effect is substantial
considering the consequences of relapse of
symptoms. Relapse may lead to missed
school/work, repeat ambulatory visits, repeat
ED visits, or readmission.
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Undesirable Effects
How substantial are the undesirable anticipated effects?
JUDGEMENT
○
●
○
○
○
○

Large
Moderate
Small
Trivial
Varies
Don't know

RESEARCH EVIDENCE

ADDITIONAL CONSIDERATIONS

Nausea, vomiting, and GI distress are noted undesirable effects of both
dexamethasone and prednisolone. Side effects (SMD 0.03; 95% CI (0.38, 0.44) in the first 7-10 days, while rarely reported, showed no
differences between the treatment groups (Rowe, B. H., Spooner, C. H.,
Ducharme, F. M., Bretzlaff, J. A., & Bota, G. W., 2001).

Theoretically, a longer treatment course may
increase the risk of adrenal suppression.
Anecdotally, the committee notes more
neuropsychiatric side effects (labile mood,
poor sleep) with prednisolone compared to
dexamethasone.

Certainty of evidence
What is the overall certainty of the evidence of effects?
JUDGEMENT
○
●
○
○
○

RESEARCH EVIDENCE

Very low
Low
Moderate
High
No included studies

ADDITIONAL CONSIDERATIONS

While systemic corticosteroids are standard of care for asthma
exacerbation, the overall certainty of the evidence is low to very low
that dexamethasone vs prednisolone show differences in relapse of
symptoms.

Values
Is there important uncertainty about or variability in how much people value the main outcomes?
JUDGEMENT

RESEARCH EVIDENCE

○ Important uncertainty or
variability
○ Possibly important uncertainty
or variability
● Probably no important
uncertainty or variability
○ No important uncertainty or
variability

As there was no substantial difference with effect on relapse of
symptoms for dexamethasone compared to prednisolone and the
variability between studies reflects a 'no difference' in outcome,
clinicians are left to determine best choice of corticosteroid for their
setting based on ease of provision and likelihood of compliance.
However, there is probably no important variability as to how much
clinicians value the outcome of no relapse of symptoms.

ADDITIONAL CONSIDERATIONS
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Balance of effects
Does the balance between desirable and undesirable effects favor the intervention or the comparison?
JUDGEMENT

RESEARCH EVIDENCE

○ Favors the comparison
No difference in desirable or undesirable effects were found to support
○ Probably favors the comparison either dexamethasone or prednisolone within the literature reviews.
○ Does not favor either the
intervention or the comparison
● Probably favors the
intervention
○ Favors the intervention
○ Varies
○ Don't know

ADDITIONAL CONSIDERATIONS
Consideration of additional effects (other than
relapse of symptoms) favors the intervention
(dexamethasone). Dexamethasone is easier to
administer (often 1 dose in the care setting
before discharge home), less expensive, and
essentially eliminates the issue of
noncompliance. Noncompliance with
prednisolone could be related to treatment
duration, poor palatability, side effects, cost
and/or the process of filling the prescription.

Resources required
How large are the resource requirements (costs)?
JUDGEMENT
○
○
○
●
○
○
○

Large costs
Moderate costs
Negligible costs and savings
Moderate savings
Large savings
Varies
Don't know

RESEARCH EVIDENCE

ADDITIONAL CONSIDERATIONS

Outside of CM (Children s Mercy), prednisolone costs for a five-day
course can range from $18.00 to $48.00 compared to dexamethasone
pricing for a one-to-two-day course costs $11.00 to $32.00 based on
insurance and pharmacy.

Overall, dexamethasone cost for the
treatment course is less than that of
prednisolone.
According to CM standard charges for 2022,
the self-pay costs per unit are as follows:
Dexamethasone 12mg/12ml oral solution $11.77
Dexamethasone 4mg tablet - $8.29
Prednisolone 3mg/ml oral solution - $4.16 x 5
days
Prednisone 10mg tab - $3.88 x 5 days
Prednisone 20mg tab - $3.97 x 5 days
Additional costs include the time, effort, and
transportation needed to get a prednisolone
prescription filled at a pharmacy, compared to
receiving dexamethasone in the care setting
prior to discharge.
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Certainty of evidence of required resources
What is the certainty of the evidence of resource requirements (costs)?
JUDGEMENT
○
○
●
○
○

RESEARCH EVIDENCE

Very low
Low
Moderate
High
No included studies

ADDITIONAL CONSIDERATIONS

The majority of patients will take either dexamethasone or the first dose
of prednisolone in the care setting (urgent care, emergency department,
inpatient) so cost for initial dosing would be the same regarding
resources of staff and staging. The only difference would be the cost in
drug pricing.

Cost effectiveness
Does the cost-effectiveness of the intervention favor the intervention or the comparison?
JUDGEMENT

RESEARCH EVIDENCE

○ Favors the comparison
○ Probably favors the comparison
○ Does not favor either the
intervention or the comparison
○ Probably favors the
intervention
● Favors the intervention
○ Varies
○ No included studies

The cost effectiveness would favor the dexamethasone (intervention)
with an average of $7.00 to $16.00 less, depending on insurance and
pharmacy. Additional cost savings for dexamethasone include no need
for time or transportation to go to a pharmacy.

ADDITIONAL CONSIDERATIONS

Equity
What would be the impact on health equity?
JUDGEMENT
○
○
○
●
○
○
○

Reduced
Probably reduced
Probably no impact
Probably increased
Increased
Varies
Don't know

RESEARCH EVIDENCE

ADDITIONAL CONSIDERATIONS

Fifty percent to 70% of participants were either of Black race or Hispanic
ethnicity. The majority of initial visits were through a medical care
settings' emergency department.
The use of dexamethasone allows for equal efficacy (based on relapse of
symptoms) without the impact of inequalities potentially posed by
prednisolone. Some subpopulations may have more challenges related
to transportation to a pharmacy and medication costs/medical
insurance. Literacy or language barriers may impact the efficacy of
prescription instructions.
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Acceptability
Is the intervention acceptable to key stakeholders?
JUDGEMENT
○
○
○
●
○
○

No
Probably no
Probably yes
Yes
Varies
Don't know

RESEARCH EVIDENCE

ADDITIONAL CONSIDERATIONS

It is acceptable to key stakeholders to use an equally effective, yet less
expensive medication. Stakeholders also value the increased ease of
administration (fewer doses, better palatability) of the intervention
(dexamethasone) which may improve compliance.

Feasibility
Is the intervention feasible to implement?
JUDGEMENT
○
○
○
●
○
○

No
Probably no
Probably yes
Yes
Varies
Don't know

RESEARCH EVIDENCE

ADDITIONAL CONSIDERATIONS

The intervention is feasible to implement. It is available in CM urgent
care, emergency department, and inpatient settings. The first dose of
systemic corticosteroid is already given in the care setting, so the use of
dexamethasone does not create additional processes. Medication access
and administration of dexamethasone is more feasible than prednisolone
for patients and their families.
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SUMMARY OF JUDGEMENTS
JUDGEMENT
PROBLEM

No

Probably no

Probably yes

Yes

Varies

Don't know

DESIRABLE EFFECTS

Trivial

Small

Moderate

Large

Varies

Don't know

UNDESIRABLE
EFFECTS

Large

Moderate

Small

Trivial

Varies

Don't know

CERTAINTY OF
EVIDENCE

Very low

Low

Moderate

High

VALUES

Important
uncertainty or
variability

Possibly
important
uncertainty or
variability

Probably no
important
uncertainty or
variability

No important
uncertainty or
variability

BALANCE OF EFFECTS

Favors the
comparison

Probably favors
the comparison

Does not favor
either the
intervention or
the comparison

Probably favors
the
intervention

Favors the
intervention

Varies

Don't know

RESOURCES
REQUIRED

Large costs

Moderate costs

Negligible costs
and savings

Moderate
savings

Large savings

Varies

Don't know

CERTAINTY OF
EVIDENCE OF
REQUIRED
RESOURCES

Very low

Low

Moderate

High

COST EFFECTIVENESS

Favors the
comparison

Probably favors
the comparison

Does not favor
either the
intervention or
the comparison

Probably favors
the intervention

Favors the
intervention

Varies

No included
studies

EQUITY

Reduced

Probably reduced

Probably no
impact

Probably
increased

Increased

Varies

Don't know

ACCEPTABILITY

No

Probably no

Probably yes

Yes

Varies

Don't know

FEASIBILITY

No

Probably no

Probably yes

Yes

Varies

Don't know

No included
studies

No included
studies
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TYPE OF RECOMMENDATION
Strong recommendation
against the intervention

Conditional recommendation
against the intervention

○

○

Conditional recommendation
for either the intervention or
the comparison
○

Conditional
recommendation for the
intervention
●

Strong recommendation for the
intervention
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Appendix C: Albuterol dosage based on weight versus age critically appraised topic
Specific Care Question #2
In children aged 0 – 18 years with asthma and admitted to the hospital for an exacerbation, should the dosage of quick relief albuterol medicine via
metered dose inhaler (MDI) be based on weight versus based on age better for improved outcomes (decreased length of stay and respiratory scores)
and fewer side effects (increased HR, hyperactive, nausea/vomiting, arrhythmia, irritably).
Recommendations Based on Current Literature (Best Evidence) Only
No recommendation can be made for weight or age-based MDI albuterol administration, based on expert review of current literature by the Department of
EBP. No studies were found that answered the specific care question of weight versus age dosing for albuterol. When there is a lack of scientific evidence,
standard work should be developed, implemented, and monitored.
Literature Summary
Background Asthma is a chronic disease characterized by airway inflammation (Global Initiative for Asthma (GINA), 2021). Respiratory symptoms such as
chest tightness, cough, shortness of breath, wheezing, and variable expiratory airflow are common citation. Symptoms can be chronic or occur suddenly,
with acute amplification of symptoms (GINA, 2021). An accepted treatment for mild-to-moderate exacerbation is administering short-acting beta agonists
(SABA), such as albuterol, administered through an MDI (GINA, 2021). The previous dosing recommendations have been based on the number of puffs
given through MDI (Children’s Mercy Kansas City, 2016). The purpose of this review is to determine if weight-based versus age-based dosing results in
improved outcomes.
Two guidelines were identified for this review (Cloutier et al., 2020; GINA, 2021). Both guidelines were assessed using AGREE II (see Table 1).
The Global Initiative for Asthma (2020) and The National Asthma Education and Prevention Program Coordinating Committee Working Group Expert Panel
Report (EPR)-4 (Cloutier et al., 2020) do not make any recommendations for short-acting beta-agonists (SABA) based on age or weight.
Medication
Albuterol MDI (90
mcg/puff)

Dose
4-8 puffs every 20 minutes for 3 doses, then every
1-4 hours inhalation maneuver as needed. Add
mask in children <4 years

Comments
In mild-to-moderate exacerbation, MDI plus
valved-holding chamber is as effective as nebulized
therapy with appropriate administration technique
and coaching by trained personnel

Dose
4-10 puffs every 20 minutes for the first hour, After
the first hour, doses vary from 4-10 puffs every 3-4
hours up to 6-10 puffs every 1-2 hours, or more
often

Comments
Mild-to-moderate exacerbation, delivery of SABA
via MDI and spacer leads to similar improvement in
lung functions as delivery via nebulizer

(Cloutier et al., 2020)
Medication
Albuterol MDI (90
mcg/puff)
(GINA, 2021)

Study Characteristics The search for suitable studies was completed on April 1, 2021. H. Murphy, BHS RRT AE-C and M. Buchanan BHS, RRT-NPS
reviewed the 76 titles and/or abstracts found in the search and identifieda two guidelines and nine single studies believed to answer the question. After an
in-depth review of the identified guidelines and single studies, none answered the specific care question, but one guideline addressed provided general
recommendations related to the question.
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Identification of Studies
Search Strategy and Results (see Figure 1)
((“Asthma”[Majr]) AND “Metered Dose Inhalers”[Mesh]) AND “Albuterol/administration and dosage”[Majr] AND (child OR children OR pediatr* OR
paediatr*)
76 selected items
Records identified through database searching n = 76
Studies Included in this Review
Citation
No studies answered the question
Studies Not Included in this Review
Citation
Abaya et al. (2019)
Battistini (2000)
D'Vaz et al., (2019)
Muchão et al. (2016)
Parlar-Chun and Arnold (2021)
Polat, Saz, and Nursoy (2011)
Ratnayake et al. (2016)
Schuh et al. (1999)
Schuh et al. (2012)

Study Type
with Exclusion Rationale
Reason for exclusion
Continuous albuterol dosing
Non-English
Dose not based on weight or age
High versus low dose
Continuous albuterol dosing
Study on high dose Salbutamol
Dose not based on weight or age
Continuous albuterol dosing
Continuous albuterol dosing

Methods Used for Appraisal and Synthesis
aRayyan is a web-based software used for the initial screening of titles and/or abstracts for this analysis (Ouzzani, Hammady, Fedorowicz & Elmagarmid,
2017).
bThe Appraisal of Guidelines Research and Evaluation II (AGREE II) is an international instrument used to assess the quality and reporting of clinical practice
guidelines for this analysis (Brouwers et al. 2010).
cThe Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram depicts the process in which literature is searched,
screened, and eligibility criteria is applied (Moher, Liberati, Tetzlaff, & Altman, 2009).
aOuzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016). Rayyan-a web and mobile app for systematic reviews. Systematic Reviews, 5(1),
210. Doi:10.1186/s13643-016-0384-4
bBrouwers, M.C. et al. for the AGREE Next Steps Consortium. (2010) AGREE II: Advancing guideline development, reporting and evaluation in
healthcare. Canadian Medical Association Journal, 182, E839-842. Retrieved from https://www.agreetrust.org/wp-content/uploads/2017/12/AGREEII-Users-Manual-and-23-item-Instrument-2009-Update-2017.pdf
cMoher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA
Statement. PloS Med 6(7): e1000097. Doi:10.1371/journal.pmed1000097 For more information, visit www.prisma-statement.org.
Question Originator
H. Murphy, BHS, RRT AE-C
Medical Librarian Responsible for the Search Strategy
K. Swaggart, MLIS, AHIP
EBP Team or EBP Scholar’s Responsible for Analyzing the Literature
T. Bontrager, MSN, RN, CPEN
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J. Dusin, MS, RD, LD, CPHQ
J. Edwards, RN, MSN, CPEN
K. Hess, PharmD
H. Murphy, BHS RRT AE-C
A. Wilson, BSN, RN, CPN
EBP Team Member Responsible for Reviewing, Synthesizing, and Developing this Document
J. Dusin, MS, RD, LD, CPHQ
Acronyms Used in this Document
Acronym
Explanation
AGREE II
Appraisal of Guidelines Research and Evaluation II
CAT
Critically Appraised Topic
EBP
Evidence Based Practice
EPR
Expert Panel Report
GINA
Global Initiative for Asthma
MDI
Metered dose inhaler
PRISMA
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
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Figure 1
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA)c
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Appendix D: Power Plan for Ambulatory Clinics
Being finalized, will add once available.

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is
different, and those individuals involved in providing health care are expected to use their judgment in determining
what is in the best interests of the patient based on the circumstances existing at the time. It is impossible to
anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines
should guide care with the understanding that departures from them may be required at times.
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Appendix E: Quick Notes for Urgent Care
Being finalized, will add once available.

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is
different, and those individuals involved in providing health care are expected to use their judgment in determining
what is in the best interests of the patient based on the circumstances existing at the time. It is impossible to
anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines
should guide care with the understanding that departures from them may be required at times.
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Appendix F: Power Plan for Emergency Department

Mild Asthma Exacerbation Subphase:
Being finalized, will add once available.
Moderate Asthma Exacerbation Subphase:
Being finalized, will add once available.
Severe Asthma Exacerbation subphase:
Being finalized, will add once available.

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is
different, and those individuals involved in providing health care are expected to use their judgment in determining
what is in the best interests of the patient based on the circumstances existing at the time. It is impossible to
anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines
should guide care with the understanding that departures from them may be required at times.
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Appendix G: Power Plan for Pediatric Intensive Care

Respiratory Orders with filtered order sentences

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is
different, and those individuals involved in providing health care are expected to use their judgment in determining
what is in the best interests of the patient based on the circumstances existing at the time. It is impossible to
anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines
should guide care with the understanding that departures from them may be required at times.
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Consults/Therapy and Labs

Continuous Medications/Fluids

Medications

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is
different, and those individuals involved in providing health care are expected to use their judgment in determining
what is in the best interests of the patient based on the circumstances existing at the time. It is impossible to
anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines
should guide care with the understanding that departures from them may be required at times.
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Appendix H: Power Plan for Hospital Medicine

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is
different, and those individuals involved in providing health care are expected to use their judgment in determining
what is in the best interests of the patient based on the circumstances existing at the time. It is impossible to
anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines
should guide care with the understanding that departures from them may be required at times.
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Mild Asthma Exacerbation Subphase:

Dexamethasone order sentences:

Prednisolone order sentences:

Prednisone order sentences:

Moderate Asthma Exacerbation Subphase:

Combined neb order sentences:

Magnesium sulfate order sentences:

Prednisone order sentences:

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is
different, and those individuals involved in providing health care are expected to use their judgment in determining
what is in the best interests of the patient based on the circumstances existing at the time. It is impossible to
anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines
should guide care with the understanding that departures from them may be required at times.
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Severe Asthma Exacerbation subphase:

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is
different, and those individuals involved in providing health care are expected to use their judgment in determining
what is in the best interests of the patient based on the circumstances existing at the time. It is impossible to
anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines
should guide care with the understanding that departures from them may be required at times.
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Appendix I: AGREE II Assessment for Children’s Mercy Hospital’s Asthma CPG
AGREE IIa Summary for this Clinical Practice Guideline*
Domain

Percent Agreement

Scope and purpose

100%

Stakeholder involvement

92%

Rigor of development

99%

Clarity and presentation
Applicability

100%
98%

Editorial independence
100%
Reviewer’s recommendation for
Adopt the utilization of this guideline
guideline use
*Note: This assessment reflects the views obtained from one external clinician and one internal clinician.

* These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is
different, and those individuals involved in providing health care are expected to use their judgment in determining
what is in the best interests of the patient based on the circumstances existing at the time. It is impossible to
anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly, these guidelines
should guide care with the understanding that departures from them may be required at times.

